GW-5282
/ Dizal Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 10, 2026
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=203 | Not yet recruiting | Sponsor: Dizal Pharmaceuticals
New P1/2 trial • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1